Delving into the Latest Updates on Peginterferon alfa-2a(Rhein-Minapharm) with Synapse

Overview

Basic Info

Drug Type

Interferons, Biosimilar

Synonyms

Hansenula-derived peginterferon alpha-2a (Rhein-Minapharm), PEG-IFN alpha-2a (Rhein-Minapharm), PEG-interferon alpha-2a (Rhein-Minapharm)

+ [3]

Target

IFNAR

Action

agonists

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists)

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis C

Inactive Indication-

Originator Organization

Rhein-Minapharm

Active Organization

Rhein-Minapharm

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Egypt (01 Jan 2015),

Hepatitis C

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 32821

The sequence is quoted from: *****

Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations - Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations

Start Date01 Mar 2014

Sponsor / Collaborator-

100 Clinical Results associated with Peginterferon alfa-2a(Rhein-Minapharm)

Login to view more data

100 Translational Medicine associated with Peginterferon alfa-2a(Rhein-Minapharm)

Login to view more data

100 Patents (Medical) associated with Peginterferon alfa-2a(Rhein-Minapharm)

Login to view more data

429

Literatures (Medical) associated with Peginterferon alfa-2a(Rhein-Minapharm)

01 Apr 2025·Journal of Hepatology

Critical perspectives on the efficacy of PegIFN-α-2a: Beyond initial findings

Letter

Author: Yu, Ting ; Shan, Dan ; Chen, Dong ; Yang, Yu

12 Jun 2024·Euroasian journal of hepato-gastroenterology

Efficacy of Pegylated Interferon-alpha-2a in Chronic Hepatitis Delta: Experience from a Tertiary Care Hospital in Karachi

Article

Author: Butt, Nazish ; Hussain, Riaz ; Arisar, Fakhar A Qazi ; Usmani, Muhammad T ; Mughal, Saba

BackgroundChronic hepatitis D (CHD) along with chronic hepatitis B (CHB) is an important cause of morbidity and mortality in patients with cirrhosis. It is a potentially curable infection that has long awaited a good treatment option.ObjectiveTo ascertain the efficacy of pegylated interferon (PEG-IFN)-alpha-2a in patients suffering from CHD. A tertiary care hospital experience from Pakistan.Materials and methodsThe study included 207 CHD polymerase chain reaction (PCR)-positive patients treated with PEG-IFN-alpha-2a between July 2020 and October 2022. Virological response rate (PCR negative) at weeks 24 and 48 was the primary endpoint. Secondary outcomes included partial response (>2 log reduction in PCR) and treatment failure rate (<2 log reduction in PCR).ResultsA total of 187 patients started PEG-IFN therapy, and 148 patients completed the assigned 48 weeks of therapy. Patients' mean age was 25.7 years with 65% being males. The virological response rate was 40.5% at week 24 and 32.4% at week 48. The partial response rate was 24% at both weeks 24 and 48. The treatment failure rate was 36% at week 24 and 44% at week 48. Hemoglobin, white blood cell (WBC) count, and total bilirubin were found to be predictive of treatment response. Side effects led to treatment discontinuation among eighteen patients and one patient died due to hepatic failure.ConclusionTherapy with PEG-IFN-alpha-2a shows suboptimal outcomes in patients with CHD. There is a strong need for more effective alternate therapies for CHD patients.How to cite this articleButt N, Usmani MT, Hussain R, et al. Efficacy of Pegylated Interferon-alpha-2a in Chronic Hepatitis Delta: Experience from a Tertiary Care Hospital in Karachi. Euroasian J Hepato-Gastroenterol 2024;14(1):51-55.

27 May 2024·Ocular Immunology and Inflammation

Effectiveness of Pegylated Interferon Alpha-2a in Post-Uveitic Macular Edema Previously Responding to Non-Pegylated Interferon

Article

Author: Gozzi, F. ; Adani, C. ; Aldigeri, R. ; Cimino, L. ; De Simone, L. ; Bolletta, E. ; Mastrofilippo, V. ; Salvarani, C. ; Gentile, P.

PURPOSETo evaluate the efficacy of pegylated interferon (PEG-IFN) alpha-2a to treat post-uveitic relapsing macular edema (ME) after withdrawal of non-PEG IFN alpha-2a or 2b to maintain treatment efficacy.METHODSThis retrospective study investigated subjects with post-uveitic ME who received weekly subcutaneous PEG-IFN alpha-2a injections. Comparisons between baseline central macular thickness (CMT) and best-corrected visual acuity (BCVA) and those at all follow-up visits were made.RESULTSSix patients (nine eyes) were treated and followed up for six months. CMT (mean [standard deviation]) decreased from 375[117] to 283[39] μm after one month (p < 0.001), remaining significantly lower up to the final follow-up visit at six months (275[38] μm, p = 0.008), and BCVA (0.21[0.16] logMAR at baseline) showed an improvement of 0.12[0.11] logMAR (p = 0.026) at six months. Neither recurrences nor any serious adverse events were recorded.CONCLUSIONSPost-uveitic ME patients were effectively and safely treated with PEG-IFN alpha-2a.

100 Deals associated with Peginterferon alfa-2a(Rhein-Minapharm)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02747	-	L03AB11	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hepatitis C	Egypt	Rhein-Minapharm	01 Jan 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCD2023	Not Applicable	Cutaneous T-Cell Lymphoma	105	PEG IFN a-2a	(hzkyiciucf) = lrzumdwdys ygmfgbusco (hjehmgemnk ) View more	-	08 Jul 2023
IAS2015	Not Applicable	HIV Infections \| Hepatitis C	-	pegIFN-a 2a 180 mg/week	nblaerudig(bjpkgssapk) = eaimdortrg agckqizybe (uwknggdnzq ) View more	-	01 Jan 2015
				pegIFN-a 2a 360 mg/week	nblaerudig(bjpkgssapk) = xphonaapwr agckqizybe (uwknggdnzq ) View more
ASN2010	Not Applicable	Hepatitis C, Chronic	28	PEGIFN-alpha-2a + Ribavirin	osmhidkmqh(pfbafrjjxf) = Dose reductions of PEGIFN and ribavirin were required for hematological side effects eodibqbzxg (gsxpjftwey ) View more	Negative	16 Nov 2010
IAS2010	Not Applicable	HIV Infections \| Hepatitis C, Chronic	-	peginterferon alpha-2a (CASE group)	dzszuhdugk(qysnacrkbu) = 17(46%) patients in CASE group and 15(45%) in CONTROL group experienced adverse events (AEs) (p=0.99) lsskrrirvx (nblooaynuo ) View more	-	01 Jan 2010
				peginterferon alpha-2a (CONTROL group)
IAS2008	Not Applicable	Coinfection	105	PEG-INF alpha-2a	lgjeehecxs(oejlylvjuv) = gbnjsayijk khwqpysamj (hqozzkhkcc )	-	01 Jan 2008
				PEG-INF alpha-2b	lgjeehecxs(oejlylvjuv) = sjwikepbnb khwqpysamj (hqozzkhkcc )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data